CIK 0000907654 · Non-accelerated filer<br>Smaller reporting company
Oruka Therapeutics, Inc.
Sign in to watch- Ticker
- ORKA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 363855489
- Phone
- 650-606-7910
- Business address
- 855 OAK GROVE AVE., SUITE 100, MENLO PARK, CA, 94025
- Former names
- ARCA biopharma, Inc., NUVELO INC, HYSEQ INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $20,653,308
- in 17 filings, $20.2M under 10b5-1 plans
Net −$20,653,308. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Klein Lawrence Otto −$11.6M Chief Executive Officer sold 12% of stake
- Agarwal Arjun −$2.8M Senior Vice President, Finance sold 68% of stake
- Goncalves Joana −$2.0M Chief Medical Officer sold 41% of stake
- BALL KRISTINE M −$1.9M Director sold 100% of stake
- Quinlan Paul T −$1.7M General Counsel sold 40% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-17 | Goncalves Joana Chief Medical Officer | Option exercise · Employee Warrant (right to buy) 10b5-1 | −3,500 | 168,492 | ||
| 2026-08-14 | Quinlan Paul T General Counsel | Option exercise 10b5-1 | +10,000 | $7.80 | $78K | 41,034 |
| 2026-08-14 | Quinlan Paul T General Counsel | Option exercise 10b5-1 | +42,000 | $12.50 | $525K | 83,034 |
| 2026-08-14 | Quinlan Paul T General Counsel | Sale 10b5-1 | −3,630 | $106.05 | $385K | 79,404 |
| 2026-08-14 | Quinlan Paul T General Counsel | Sale 10b5-1 | −10,434 | $107.14 | $1.1M | 68,970 |
| 2026-08-14 | Quinlan Paul T General Counsel | Sale 10b5-1 | −14,696 | $107.97 | $1.6M | 54,274 |
| 2026-08-14 | Quinlan Paul T General Counsel | Sale 10b5-1 | −10,200 | $109.11 | $1.1M | 44,074 |
| 2026-08-14 | Quinlan Paul T General Counsel | Sale 10b5-1 | −9,193 | $110.00 | $1.0M | 34,881 |
| 2026-08-14 | Quinlan Paul T General Counsel | Sale 10b5-1 | −3,847 | $111.14 | $428K | 31,034 |
| 2026-08-14 | Quinlan Paul T General Counsel | Option exercise · Employee Warrant (right to buy) 10b5-1 | −10,000 | 89,996 | ||
| 2026-08-14 | Quinlan Paul T General Counsel | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −42,000 | 120,500 | ||
| 2026-08-13 | Agarwal Arjun Senior Vice President, Finance | Option exercise 10b5-1 | +8,542 | $12.50 | $107K | 23,854 |
| 2026-08-13 | Agarwal Arjun Senior Vice President, Finance | Option exercise 10b5-1 | +1,458 | $34.39 | $50K | 25,312 |
| 2026-08-13 | Agarwal Arjun Senior Vice President, Finance | Sale 10b5-1 | −2,100 | $104.67 | $220K | 23,212 |
| 2026-08-13 | Agarwal Arjun Senior Vice President, Finance | Sale 10b5-1 | −2,132 | $105.57 | $225K | 21,080 |
| 2026-08-13 | Agarwal Arjun Senior Vice President, Finance | Sale 10b5-1 | −1,268 | $106.63 | $135K | 19,812 |
| 2026-08-13 | Agarwal Arjun Senior Vice President, Finance | Sale 10b5-1 | −2,142 | $107.71 | $231K | 17,670 |
| 2026-08-13 | Agarwal Arjun Senior Vice President, Finance | Sale 10b5-1 | −2,358 | $108.46 | $256K | 15,312 |
| 2026-08-13 | Agarwal Arjun Senior Vice President, Finance | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −8,542 | 92,917 | ||
| 2026-08-13 | Agarwal Arjun Senior Vice President, Finance | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −1,458 | 59,792 |
Page 6 of 18 · 346 trades